


TFAP

Cat. No.:	HY-112731		
CAS No.:	1011244-68-0		
Molecular Formula:	C ₁₃ H ₁₀ F ₃ N ₃ O		
Molecular Weight:	281.23		
Target:	COX; Endogenous Metabolite		
Pathway:	Immunology/Inflammation; Metabolic Enzyme/Protease		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	2 years
		-20°C	1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 155 mg/mL (551.15 mM)
 * "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.5558 mL	17.7790 mL	35.5581 mL
	5 mM	0.7112 mL	3.5558 mL	7.1116 mL
	10 mM	0.3556 mL	1.7779 mL	3.5558 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
Solubility: ≥ 2.58 mg/mL (9.17 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.58 mg/mL (9.17 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil
Solubility: 2.58 mg/mL (9.17 mM); Clear solution; Need warming

BIOLOGICAL ACTIVITY

Description

TFAP is a selective cyclooxygenase-1 (COX-1) inhibitor, with an IC₅₀ of 0.8 μM.

IC₅₀ & Target

COX-1
0.8 μM (IC₅₀)

In Vitro

TFAP is a selective cyclooxygenase-1 (COX-1) inhibitor, with an IC₅₀ of 0.8 μM, while that against COX-2 is over 200 μM.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Kakuta H, et al. Identification of urine metabolites of TFAP, a cyclooxygenase-1 inhibitor. Bioorg Med Chem Lett. 2010 Mar 15;20(6):1840-3.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA